Lion TCR
Lion TCR Pte Ltd is a biotech company engineering virus-specific T cells with mRNA technology and testing their efficacy in patients with virus-related cancers (HBV-HCC and EBV related malignancies) and chronic viral infections. Established in 2015, the company has been the first to initiate and run clinical trials (Phase I and II) for the treatment of HBV related HCC relapses in liver transplant patients and in primary HCC in Singapore and China.
T Cell Diagnostics (TCD)
TCD was founded in 2021 to provide immunological services to companies testing novel antiviral therapies against different viruses (HBV, SARS-CoV-2, HCMV and others). It provides customized services consisting of the design, execution, and analysis of various immunological test able to profile cellular immunity in different viral infection.
